Discrete Frequency Infrared Spectroscopic Imaging for Breast Histopathology
Project Number5R01EB009745-12
Former Number2R01EB009745-09
Contact PI/Project LeaderBHARGAVA, ROHIT
Awardee OrganizationUNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
Description
Abstract Text
PROJECT ABSTRACT
Infrared (IR) spectroscopic imaging directly measures the chemical composition of cells and tissues for each
pixel in the image. Using machine learning, this chemical data can be converted to pathology knowledge, without
the use of dyes or stains – providing a potentially new avenue for clinical diagnoses and research to broadly aid
public health. Since machine learning is integral to the approach, cognition of disease features can make
diagnoses faster, cheaper and more precise. Interestingly, the approach can measure the tumor’s molecular
characteristics and the microenvironment together in one shot. These capabilities can extend state of the art
pathology practice by providing multiplexed stain-free molecular data and predictive models involving spatial and
chemical information from multiple cell types. However, there are significant challenges and engineering
development needed before this vision can be realized, including: (a) an imaging system that is competitive in
measurement time with current clinical practice, (b) accurate and assured results that extend our ability beyond
routine pathology, and (c) demonstration of robust use by pathologists and non-experts in technology. In the last
project period(reported in 25 peer-reviewed publications, 2 granted patents), we developed “high-definition” (HD)
IR imaging, which is now the standard commercial configuration for IR imaging manufacturers. We also
developed the concept of “stainless staining” in which “low-definition” IR images appear to look like low-resolution
stained images. We also demonstrated highly accurate breast tissue classification for a small number of
pathologies. In this project period, we propose an advanced IR imaging system (newly designed optics,
scanning) to make the technology powerful enough to provide a sample-to-image time of ~10 min for large
surgical resections. This allows HD imaging in real time and will allow images, such as from stainless stains, be
near the quality of those used by clinicians and researchers. Technological innovations lie in a design that is the
first novel re-design of IR imaging in over 40 years and performance that is higher in speed, accuracy and image
quality than ever before. Another critical part of our approach is to develop appropriate computational pipelinesfor
extant problems in breast pathology. In addition to traditional models, we will validate the emerging tools of deep
learning when appropriate. Finally, these technological realizations are followed by validation for a set of
important problems in breast cancer care and research. The solutions will be rigorously evaluated against
pathologist diagnoses, using high-quality, annotated data from 400 patients’ surgical resections and multiple
tissue microarrays. Consequently, protocols for a number of identified pain points in breast pathology will result
in addition to the technological progress, making the approach ready for use.
Public Health Relevance Statement
PROJECT NARRATIVE
The goal of this project period is to make infrared (IR) spectroscopic imaging practical for routine pathology and
evaluate whether it’s application can improve patient outcomes. In the last project period, we developed “high
definition” IR imaging that provided unprecedented quality and accuracy in pathology but the instrument was too
slow to be practical and did not take advantage of emerging spatial-spectral machine learning methods like deep
learning. Here we propose a new instrument design and a robust, accurate and precise analytical approach to
speed up sample-to-information time, a critical step in becoming practical for pathology laboratory and intra-
operative use.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
041544081
UEI
Y8CWNJRCNN91
Project Start Date
01-May-2010
Project End Date
30-November-2025
Budget Start Date
01-December-2024
Budget End Date
30-November-2025
Project Funding Information for 2025
Total Funding
$405,803
Direct Costs
$262,232
Indirect Costs
$143,571
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Biomedical Imaging and Bioengineering
$405,803
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01EB009745-12
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EB009745-12
Patents
No Patents information available for 5R01EB009745-12
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EB009745-12
Clinical Studies
No Clinical Studies information available for 5R01EB009745-12
News and More
Related News Releases
No news release information available for 5R01EB009745-12
History
No Historical information available for 5R01EB009745-12
Similar Projects
No Similar Projects information available for 5R01EB009745-12